Etherna Immunotherapies competitive analysis

Latest publications and patents of Etherna Immunotherapies New

Explore the latest publications and patents granted to Etherna Immunotherapies, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Etherna Immunotherapies against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 25, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

High-Purity Peg Lipids And Uses ThereofMODERNAJun 27, 2025
Method For Producing Rna CompositionsCUREVACOct 3, 2024
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses ThereofMODERNAFeb 20, 2023
Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNADec 2, 2022
Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses ThereofMODERNAAug 31, 2022
Rna Containing Composition For Treatment Of Tumor DiseasesCUREVACMar 26, 2020
Optimised Injection Formulation For MrnaCUREVACMar 18, 2020
Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVACFeb 3, 2020
Immunostimulation By Chemically Modified RnaCUREVACSep 6, 2018
Combination Of Vaccination And Inhibition Of The Pd-1 PathwayCUREVACMay 23, 2018

Latest PTAB cases involving Etherna Immunotherapies

Discover the latest PTAB cases involving Etherna Immunotherapies, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Etherna Immunotherapies with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
ETHERNA IMMUNOTHERAPIES10 - - - Highly Aggressive
CUREVAC - 62 - 1Non-Active
CUREVAC MANUFACTURING - 24 - - Non-Active
MODERNA57442Defensive